Catalio Capital Management »

Ascendis Pharma A S shares owned by Catalio Capital Management

Quarter-by-quarter ownership of Ascendis Pharma A S (ASND) shares owned by Catalio Capital Management from 13F filings

Historical chart of Catalio Capital Management investment in Ascendis Pharma A S

Tip: Access up to 7 years of quarterly data

All positions including Ascendis Pharma A S held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ascendis Pharma A S by Catalio Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $29M 145k 198.81

More positions owned by Catalio Capital Management

Eli Lilly & Co. (LLY)
Abbvie (ABBV)
Bridgebio Pharma (BBIO)
Intuitive Surgical Com New (ISRG)
Ascendis Pharma A/s Sponsored Adr (ASND)
Soleno Therapeutics (SLNO)
Dianthus Therapeutics (DNTH)
Boston Scientific Corporation (BSX)
Syndax Pharmaceuticals (SNDX)
Cytokinetics Com New (CYTK)
Natera (NTRA)
Regeneron Pharmaceuticals (REGN)
Structure Therapeutics Sponsored Ads (GPCR)
Uniqure Nv SHS (QURE)
Disc Medicine (IRON)

View all positions for Catalio Capital Management

Top funds holding Ascendis Pharma A S

RA Capital Management
Westfield Capital Management Company
venBio Select Advisor
FMR
Henderson Group
Lombard Odier Asset Management
Artisan Partners Limited Partnership
Capital Research and Management Company - Division 3
T. Rowe Price Investment Management
Massachusetts Financial Services
Wellington Management Company
Franklin Resources
Perceptive Advisors
Invesco
Polar Capital Holdings

View all funds holding Ascendis Pharma A S